UM  > Faculty of Health Sciences
Residential Collegefalse
Status已發表Published
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024
Lau, George1; Obi, Shuntaro2; Zhou, Jian3; Tateishi, Ryosuke4; Qin, Shukui5; Zhao, Haitao6; Otsuka, Motoyuki7; Ogasawara, Sadahisa8; George, Jacob9; Chow, Pierce K.H.10; Cai, Jianqiang11; Shiina, Shuichiro12; Kato, Naoya13; Yokosuka, Osamu14; Oura, Kyoko15; Yau, Thomas16; Chan, Stephen L.17; Kuang, Ming18; Ueno, Yoshiyuki19; Chen, Minshan20; Cheng, Ann Lii21; Cheng, Gregory22,58; Chuang, Wan Long23; Baatarkhuu, Oidov24; Bi, Feng25; Dan, Yock Young26; Gani, Rino A.27; Tanaka, Atsushi28; Jafri, Wasim29; Jia, Ji Dong30; Kao, Jia Horng31; Hasegawa, Kiyoshi32; Lau, Patrick33; Lee, Jeong Min34; Liang, Jun35; Liu, Zhenwen36; Lu, Yinying37; Pan, Hongming38; Payawal, Diana A.39; Rahman, Salimur40; Seong, Jinsil41; Shen, Feng42; Shiha, Gamal43,59,60,61; Song, Tianqiang44; Sun, Hui Chuan45; Masaki, Tsutomu15; Sirachainan, Ekaphop46; Wei, Lai47; Yang, Jin Mo48; Sallano, Jose D.49; Zhang, Yanqiao50; Tanwandee, Tawesak51; Dokmeci, AKadir52; Zheng, Shu Sen53; fan, Jia54; Fan, Sheung Tat55; Sarin, Shiv Kumar56; Omata, Masao57
2024-12
Source PublicationHepatology International
ISSN1936-0533
Volume18Issue:6Pages:1661-1683
Abstract

In Asia–Pacific region, hepatocellular carcinoma is a serious health threat attributing to over 600,000 deaths each year and account for over 70% of global cases. Clinically, the major unmet needs are recurrence after curative-intent surgery, liver transplantation or local ablation and disease progression in those with hepatocellular carcinoma not eligible for resection or failed locoregional therapy. In the recent few years, new targeted therapy and immune-checkpoint inhibitors have been registered as systemic therapy to address these issues. Notably, new forms of systemic therapy, either as first-line or second-line therapy for unresectable hepatocellular or those not eligible for locoregional therapy, are now available. New data is also emerging with the use of systemic therapy to prevent hepatocellular carcinoma recurrence after curative-intent resection or local ablation therapy and to retard disease progression after locoregional therapy. In the future, further implementation of immune-checkpoint inhibitors and other forms of immunotherapy are expected to bring a new paradigm to the management of hepatocellular carcinoma. New insight related to immune-related adverse events with the use of immunotherapy has allso enabled optimization of the therapeutic approach to patients with hepatocellular carcinoma. The purpose of this clinical practice guideline is to provide an up-to-date recommendation based on clinical evidence and experience from expert Asia–Pacific key opinion leaders in the field of hepatocellular carcinoma. Three key questions will be addressed, namely: (1) Which patients with hepatocellular carcinoma should be considered for systemic therapy? (2) Which systemic therapy should be used? (3) How should a patient planned for immune checkpoint-based systemic therapy be managed and monitored?

KeywordHepatocellular Carcinoma Systemic Therapy Guidelines The Asian Pacific Association For The Study Of The Liver
DOI10.1007/s12072-024-10732-z
URLView the original
Indexed BySCIE
Language英語English
WOS Research AreaGastroenterology & Hepatology
WOS SubjectGastroenterology & Hepatology
WOS IDWOS:001361536900001
PublisherSPRINGER, ONE NEW YORK PLAZA, SUITE 4600 , NEW YORK, NY 10004, UNITED STATES
Scopus ID2-s2.0-85209718693
Fulltext Access
Citation statistics
Document TypeJournal article
CollectionFaculty of Health Sciences
Corresponding AuthorLau, George
Affiliation1.Humanity and Health Clinical Trial Center, Humanity and Health Medical Group, Zhongshan Hospital, Fudan University, Shanghai, Hong Kong
2.Department of Internal Medicine, Teikyo University Chiba Medical Center, Chiba, Japan
3.Department of Liver Surgery and Transplantation, Key Laboratory of Carcinogenesis and Cancer Invasion (Fudan University), Ministry of Education, Shanghai Key Laboratory of Organ Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Zhongshan Hospital, Fudan University, Shanghai, China
4.Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
5.Cancer Centre of Jinling Hospital, Nanjing University of Chinese Medicine, Nanjing, China
6.Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & amp; Peking Union Medical College, Beijing, China
7.Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, 700-8558, Japan
8.Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, 1-8-1 Inohana, Chuo-Ku, 260-8670, Japan
9.Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Westmead, 2145, Australia
10.Department of HPB Surgery and Transplantation, Duke-NUS Medical School, National Cancer Center Singapore and Singapore General Hospital, Surgery Academic Clinical Program, Singapore, Singapore
11.Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
12.Department of Gastroenterology, Juntendo University, Bunkyo-Ku, 2-1-1, Hongo, Tokyo, 113-8421, Japan
13.Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan
14.Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan
15.Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Miki, 1750-1 Ikenobe, Kita, Kagawa, 761-0793, Japan
16.Department of Medicine, The University of Hong Kong, Hong Kong
17.Department of Clinical Oncology, State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, The Chinese University of Hong Kong, Hong Kong
18.Center of Hepato-Pancreato-Biliary Surgery, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China
19.Faculty of Medicine, Department of Gastroenterology, Faculty of Medicine, Yamagata University, Yamagata, 2-2-2 Iida-Nishi, 990-9585, Japan
20.Department of Liver Surgery, Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China
21.Department of OncologyDepartment of Medical OncologyGraduate Institute of OncologyDepartment of Internal Medicine, National Taiwan University Cancer CenterNational Taiwan University HospitalNational Taiwan University College of Medicine, Taipei, Taiwan
22.Humanity and Health Clinical Trial Center, Humanity & amp; Health Medical Group, Hong Kong
23.Hepatobiliary Division, Department of Internal Medicine, and Hepatitis Center, Center for Infectious Disease and Cancer Research, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
24.School of Medicine, Mongolian National University of Medical Sciences, Ulan Bator, Mongolia
25.Department of Medical Oncology, Laboratory of Molecular Targeted Therapy in Oncology, West China Hospital, Sichuan University, Chengdu, China
26.Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore, Singapore
27.Hepatobiliary Division, Staff Medic Group of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, 10430, Indonesia
28.Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan
29.The Aga Khan University Hospital, Karachi, Pakistan
30.Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China
31.Department of Internal Medicine Division of Gastroenterology and Hepatology, Department of Internal MedicineHepatitis Research Center, Graduate Institute of Clinical Medicine, National Taiwan University Hospital Bei-Hu BranchNational Taiwan University HospitalNational Taiwan University College of Medicine, Taipei, Taiwan
32.Department of Surgery, Graduate School of Medicine, Hepato-Biliary-Pancreatic Surgery Division, The University of Tokyo, Tokyo, Japan
33.Humanity and Health Clinical Trial Center, Humanity & Health Medical Group, Hong Kong SAR, China
34.Department of Radiology, Seoul National University College of Medicine, Seoul, South Korea
35.Department of Medical Oncology, Peking University International Hospital, Beijing, China
36.Senior Department of Hepatology, The Fifth Medical Center of Chinese People’s Liberation, Army General Hospital, Beijing, China
37.Department of Comprehensive Liver Cancer Center, The Fifth Medical Center of Chinese, PLA General Hospital, Beijing, China
38.Department of Medical Oncology, College of Medicine, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China
39.Department of Medicine, Fatima University Medical Center, Manila, Philippines
40.Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, 1000, Bangladesh
41.Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea
42.Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Navy Medical University), Shanghai, China
43.European Liver Patients’ Association (ELPA), Brussels, Belgium
44.Department of Hepatobiliary, HCC Research Center for Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China
45.Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China
46.Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
47.Hepatopancreatobiliary Center, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China
48.Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea
49.Section of Gastroenterology, University of Santo Tomas, Manila, Philippines
50.Department of Gastrointestinal Medical Oncology, Institute of Prevention and Treatment of Cancer of Heilongjiang Province, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
51.Division of Gastroenterology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
52.Department of Medicine, Ankara University School of Medicine, Ankara, Turkey
53.Department of Hepatobiliary and Pancreatic Surgery, Department of Liver Transplantation, Shulan (Hangzhou) Hospital, Zhejiang Shuren University School of Medicine, Hangzhou, China
54.Department of Liver Surgery and Transplantation, Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China
55.Liver Surgery and Transplant Centre, Hong Kong Sanatorium and Hospital, Hong Kong
56.Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India
57.Department of Gastroenterology, Yamanashi Prefectural Center Hospital, Kofu-City, Yamanashi, Japan
58.Faculty of Health Sciences, University of Macau, Macao SAR, China
59.World Hepatitis Alliance, London, United Kingdom
60.African Liver Patient Association (ALPA), Cairo, Egypt
61.The Association of Liver Patients Care (ALPC), Hepatology and Gastroenterology Unit, Internal Medicine Department, Faculty of Medicine, Mansoura University, Egyptian Liver Research Institute and Hospital (ELRIAH), El Mansoura, Sherbin, Egypt
Recommended Citation
GB/T 7714
Lau, George,Obi, Shuntaro,Zhou, Jian,et al. APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024[J]. Hepatology International, 2024, 18(6), 1661-1683.
APA Lau, George., Obi, Shuntaro., Zhou, Jian., Tateishi, Ryosuke., Qin, Shukui., Zhao, Haitao., Otsuka, Motoyuki., Ogasawara, Sadahisa., George, Jacob., Chow, Pierce K.H.., Cai, Jianqiang., Shiina, Shuichiro., Kato, Naoya., Yokosuka, Osamu., Oura, Kyoko., Yau, Thomas., Chan, Stephen L.., Kuang, Ming., Ueno, Yoshiyuki., ...& Omata, Masao (2024). APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024. Hepatology International, 18(6), 1661-1683.
MLA Lau, George,et al."APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024".Hepatology International 18.6(2024):1661-1683.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Lau, George]'s Articles
[Obi, Shuntaro]'s Articles
[Zhou, Jian]'s Articles
Baidu academic
Similar articles in Baidu academic
[Lau, George]'s Articles
[Obi, Shuntaro]'s Articles
[Zhou, Jian]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Lau, George]'s Articles
[Obi, Shuntaro]'s Articles
[Zhou, Jian]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.